A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Phase 1
50
about 3.9 years
18+
4 sites in CA, MO, NY +1
About this study
Researchers are testing a treatment called TLN-254 for people with relapsed or refractory T-cell lymphoma. The trial will last about 1430 days and aims to see if TLN-254 can fight the cancer.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take TLN-254
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Percentage of Participants With CR, Percentage of Participants With Objective Response, Percentage of Participants With PR
Secondary: Duration of Response (DOR), Number of Participants With Severity of TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0, Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Oncology